汇宇制药:注射用HY05350 I期临床试验首例受试者给药

格隆汇
Aug 04

汇宇制药公告,全资子公司汇宇海玥自主研发的 1类生物创新药注射用 HY05350(项目研发代号为“HY-0005”)正在开展用于治疗晚期实体瘤的 I 期临床试验,于近日成功完成首例受试者给药。截至 2025年 6月 30日,公司在该项目中累计研发投入约人民币 7642.82万元(未经审计)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10